Nothing Special   »   [go: up one dir, main page]

MX2017004534A - Metodos mejorados para inactivacion de enterovirus, composiciones de vacuna con adsorcion de adyuvante y reducida en dosis obtenida de los mismos. - Google Patents

Metodos mejorados para inactivacion de enterovirus, composiciones de vacuna con adsorcion de adyuvante y reducida en dosis obtenida de los mismos.

Info

Publication number
MX2017004534A
MX2017004534A MX2017004534A MX2017004534A MX2017004534A MX 2017004534 A MX2017004534 A MX 2017004534A MX 2017004534 A MX2017004534 A MX 2017004534A MX 2017004534 A MX2017004534 A MX 2017004534A MX 2017004534 A MX2017004534 A MX 2017004534A
Authority
MX
Mexico
Prior art keywords
improved methods
vaccine compositions
compositions obtained
dose reduced
enterovirus
Prior art date
Application number
MX2017004534A
Other languages
English (en)
Inventor
Shankar Pisal Sambhaji
Mhalasakant Dhere Rajeev
Kamalaji Zade Jagdish
Narayan SABALE Rajendra
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of MX2017004534A publication Critical patent/MX2017004534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a métodos mejorados de inactivación de Enterovirus por formaldehído en presencia de amortiguador de trometamina resultando en recuperación máxima de antígeno D. Adsorción subsecuente de los sIPV en hidróxido de aluminio proporciona composiciones de sIPV significativamente reducida en dosis.
MX2017004534A 2014-10-07 2015-10-06 Metodos mejorados para inactivacion de enterovirus, composiciones de vacuna con adsorcion de adyuvante y reducida en dosis obtenida de los mismos. MX2017004534A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (1)

Publication Number Publication Date
MX2017004534A true MX2017004534A (es) 2017-10-11

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004534A MX2017004534A (es) 2014-10-07 2015-10-06 Metodos mejorados para inactivacion de enterovirus, composiciones de vacuna con adsorcion de adyuvante y reducida en dosis obtenida de los mismos.

Country Status (24)

Country Link
US (1) US10485862B2 (es)
EP (2) EP3663396A1 (es)
JP (2) JP6755243B2 (es)
KR (2) KR102510744B1 (es)
CN (2) CN106999569B (es)
AU (2) AU2015334495B2 (es)
CA (1) CA2963897C (es)
CU (1) CU24510B1 (es)
CY (1) CY1123078T1 (es)
DK (1) DK3204494T3 (es)
EA (1) EA201700187A1 (es)
ES (1) ES2803578T3 (es)
HU (1) HUE049104T2 (es)
LT (1) LT3204494T (es)
MX (1) MX2017004534A (es)
MY (1) MY204389A (es)
PE (1) PE20171132A1 (es)
PH (1) PH12017500627A1 (es)
PL (1) PL3204494T3 (es)
PT (1) PT3204494T (es)
SG (2) SG10202010814RA (es)
SI (1) SI3204494T1 (es)
UA (1) UA125788C2 (es)
WO (1) WO2016063291A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3204494T (pt) * 2014-10-07 2020-07-10 Serum Institute Of India Pvt Ltd Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante
EP3454895B1 (en) 2016-05-10 2024-03-27 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
EA201900117A1 (ru) * 2016-08-26 2019-09-30 Серум Инститьют Оф Индиа Прайвит Лимитид Комбинированная вакцина и способ её производства (варианты)
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
US11478541B2 (en) 2017-11-03 2022-10-25 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
EP3717638A4 (en) 2017-11-30 2022-03-09 Takeda Vaccines, Inc. METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
WO2019155492A1 (en) * 2018-02-07 2019-08-15 Bharat Biotech International Limited A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127847A (en) * 1996-07-02 2004-06-01 Connaught Lab Polio-karma vaccine vaccines, valuable pertussis
MX2007002372A (es) * 2004-08-27 2007-05-08 Panacea Biotec Ltd Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio.
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
SI2097102T1 (sl) * 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
BR112012014689B1 (pt) * 2009-12-16 2019-11-12 Serum Institute Of India Private Limited composição imunogênica
KR20140026392A (ko) * 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
PT3204494T (pt) * 2014-10-07 2020-07-10 Serum Institute Of India Pvt Ltd Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante

Also Published As

Publication number Publication date
US10485862B2 (en) 2019-11-26
EA201700187A1 (ru) 2017-12-29
CN113368227A (zh) 2021-09-10
AU2015334495B2 (en) 2021-08-19
KR20210021148A (ko) 2021-02-24
KR20170063947A (ko) 2017-06-08
CA2963897C (en) 2023-08-22
PT3204494T (pt) 2020-07-10
NZ731341A (en) 2023-11-24
CA2963897A1 (en) 2016-04-28
JP2020203906A (ja) 2020-12-24
EP3204494B1 (en) 2020-04-01
CU24510B1 (es) 2021-05-12
SG11201702838SA (en) 2017-05-30
KR102219638B1 (ko) 2021-02-23
CY1123078T1 (el) 2021-10-29
JP7063957B2 (ja) 2022-05-09
LT3204494T (lt) 2020-07-10
MY204389A (en) 2024-08-27
KR102510744B1 (ko) 2023-03-15
CU20170044A7 (es) 2018-09-05
AU2021269395B2 (en) 2024-05-23
BR112017007089A2 (pt) 2017-12-26
UA125788C2 (uk) 2022-06-08
AU2021269395A1 (en) 2021-12-16
JP2017533899A (ja) 2017-11-16
JP6755243B2 (ja) 2020-09-16
ES2803578T3 (es) 2021-01-28
EP3204494A1 (en) 2017-08-16
CN106999569A (zh) 2017-08-01
PL3204494T3 (pl) 2020-09-21
CN106999569B (zh) 2021-06-29
PH12017500627A1 (en) 2017-09-25
EP3663396A1 (en) 2020-06-10
SI3204494T1 (sl) 2020-08-31
PE20171132A1 (es) 2017-08-09
AU2015334495A1 (en) 2017-05-25
WO2016063291A1 (en) 2016-04-28
HUE049104T2 (hu) 2020-08-28
SG10202010814RA (en) 2020-12-30
DK3204494T3 (da) 2020-07-06
US20170348411A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
PH12017500627A1 (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201790630A1 (ru) Способы получения рибозидов
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
PH12016501968A1 (en) Novel macrocyclic compounds
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
IN2014MU00455A (es)
MX2017000306A (es) Metodos para tratar hipotension.
PH12016502322B1 (en) Compounds and methods for preventing or treating malaria
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MY172369A (en) Microorganism of the genus escherichia producing l-tryptophan and method for producing l-tryptophan using the same
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12020550204A1 (en) A non-naturally occurring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
MX2016017084A (es) Composiciones y metodos para mejorar la inmunidad.
MX2018001251A (es) Respuesta inmunitaria potenciada de las especies porcinas.
MX2018003173A (es) Vacunas de salmonella choleraesuis-salmonella typhimurium.
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
IN2014CH01391A (es)
TW201613927A (en) Method for preparation of substituted imidazopyridazines
UA88646U (uk) Перфторароматичні ізомерні дифторфенілазометинфенілові етери як мономери для поліетеразометинів